LISATA THERAP.INC.DL-001 (8NE) - Net Assets
Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has net assets worth €14.60 Million EUR (≈ $17.07 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€17.74 Million ≈ $20.74 Million USD) and total liabilities (€3.14 Million ≈ $3.67 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LISATA THERAP.INC.DL-001 (8NE) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €14.60 Million |
| % of Total Assets | 82.29% |
| Annual Growth Rate | -36.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.25 |
LISATA THERAP.INC.DL-001 - Net Assets Trend (2021–2025)
This chart illustrates how LISATA THERAP.INC.DL-001's net assets have evolved over time, based on quarterly financial data. Also explore 8NE total asset value for the complete picture of this company's asset base.
Annual Net Assets for LISATA THERAP.INC.DL-001 (2021–2025)
The table below shows the annual net assets of LISATA THERAP.INC.DL-001 from 2021 to 2025. For live valuation and market cap data, see market cap of LISATA THERAP.INC.DL-001.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €14.60 Million ≈ $17.07 Million |
-50.20% |
| 2024-12-31 | €29.32 Million ≈ $34.27 Million |
-38.79% |
| 2023-12-31 | €47.89 Million ≈ $55.99 Million |
-27.79% |
| 2022-12-31 | €66.32 Million ≈ $77.54 Million |
-27.91% |
| 2021-12-31 | €92.00 Million ≈ $107.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LISATA THERAP.INC.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11163600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €579.51 Million | 3901.09% |
| Total Equity | €14.86 Million | 100.00% |
LISATA THERAP.INC.DL-001 Competitors by Market Cap
The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Valbiotis SAS
PA:ALVAL
|
$24.42 Million |
|
Green Critical Minerals Ltd
AU:GCM
|
$24.44 Million |
|
KARO INVEST a.s.
PR:KARIN
|
$24.45 Million |
|
Tek Seng Holdings Bhd
KLSE:7200
|
$24.45 Million |
|
Coal Energy S.A.
WAR:CLE
|
$24.40 Million |
|
SABUY TECHNOLOGY
BK:SABUY-R
|
$24.40 Million |
|
Canadian North Resources Inc.
V:CNRI
|
$24.40 Million |
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM
|
$24.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LISATA THERAP.INC.DL-001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,571,000 to 14,855,000, a change of -14,716,000 (-49.8%).
- Net loss of 16,586,000 reduced equity.
- New share issuances of 844,000 increased equity.
- Other factors increased equity by 1,026,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-16.59 Million | -111.65% |
| Share Issuances | €844.00K | +5.68% |
| Other Changes | €1.03 Million | +6.91% |
| Total Change | €- | -49.76% |
Book Value vs Market Value Analysis
This analysis compares LISATA THERAP.INC.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.11x to 1.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €23.14 | €2.62 | x |
| 2022-12-31 | €8.43 | €2.62 | x |
| 2023-12-31 | €5.91 | €2.62 | x |
| 2024-12-31 | €3.52 | €2.62 | x |
| 2025-12-31 | €1.68 | €2.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LISATA THERAP.INC.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9756.47%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.19x
- Recent ROE (-111.65%) is below the historical average (-66.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -29.77% | 0.00% | 0.00x | 1.05x | €-36.69 Million |
| 2022 | -81.45% | 0.00% | 0.00x | 1.10x | €-60.88 Million |
| 2023 | -43.28% | 0.00% | 0.00x | 1.14x | €-25.65 Million |
| 2024 | -67.58% | -1998.50% | 0.03x | 1.18x | €-22.94 Million |
| 2025 | -111.65% | -9756.47% | 0.01x | 1.19x | €-18.07 Million |
Industry Comparison
This section compares LISATA THERAP.INC.DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LISATA THERAP.INC.DL-001 (8NE) | €14.60 Million | -29.77% | 0.22x | $24.41 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more